Literature DB >> 35166966

Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort.

Jacob V DiBattista1, Daniel A Burkholder1, Anna S Lok2, Vincent L Chen3.   

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease is common and under-diagnosed. This study evaluated the accuracy of several previously reported indices, including hepatic steatosis index, alanine aminotransferase (ALT) method, Framingham steatosis index, and Dallas steatosis index, to diagnose hepatic steatosis in a real-world cohort.
METHODS: This study included 701 randomly selected adult patients seen in our integrated healthcare system between 2015 and 2020 with appropriate abdominal imaging and routine outpatient laboratory studies. Information on demographics, comorbidities and existing liver disease, anthropometrics, laboratory studies, and abdominal imaging was collected. The sensitivity, specificity, and C-statistic of each method in detecting hepatic steatosis based on abdominal imaging were determined.
RESULTS: 202/701 patients (28.8%) had hepatic steatosis on abdominal imaging. These patients were more likely to have metabolic syndrome components and higher body mass index. All indices performed similarly with moderate accuracy in detecting hepatic steatosis based on the C-statistic (95% confidence interval): Hepatic steatosis index 0.76 (0.72-0.79), Framingham steatosis index 0.78 (0.74-0.82), and Dallas steatosis index 0.80 (0.76-0.83). ALT method had sensitivity 44.7% (36.9-52.7%) and specificity 88.6% (85.0-91.7%). Several sensitivity analyses were performed, which did not significantly alter the performance of any index.
CONCLUSION: The findings support both the clinical utility of these indices in diagnosing hepatic steatosis in the absence of imaging in real-world settings and the research utility of these indices in generating reliable electronic medical record-based nonalcoholic fatty liver disease cohorts.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alanine aminotransferase; Dallas steatosis index; Framingham steatosis index; Hepatic steatosis; Nonalcoholic fatty liver disease; Screening

Year:  2022        PMID: 35166966     DOI: 10.1007/s10620-022-07415-w

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  26 in total

1.  Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data.

Authors:  N Husain; P Blais; J Kramer; M Kowalkowski; P Richardson; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2014-08-26       Impact factor: 8.171

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

3.  Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey.

Authors:  C E Ruhl; J E Everhart
Journal:  Aliment Pharmacol Ther       Date:  2014-11-06       Impact factor: 8.171

4.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

5.  Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.

Authors:  Jeong-Hoon Lee; Donghee Kim; Hwa Jung Kim; Chang-Hoon Lee; Jong In Yang; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon; Sang-Heon Cho; Myung-Whun Sung; Hyo-Suk Lee
Journal:  Dig Liver Dis       Date:  2009-09-18       Impact factor: 4.088

6.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.

Authors:  Zobair M Younossi; Deirdre Blissett; Robert Blissett; Linda Henry; Maria Stepanova; Youssef Younossi; Andrei Racila; Sharon Hunt; Rachel Beckerman
Journal:  Hepatology       Date:  2016-09-26       Impact factor: 17.425

Review 7.  Noninvasive assessment of hepatic steatosis.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Claude B Sirlin
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-06       Impact factor: 11.382

8.  Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis.

Authors:  Michelle T Long; Alison Pedley; Lisandro D Colantonio; Joseph M Massaro; Udo Hoffmann; Paul Muntner; Caroline S Fox
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-01       Impact factor: 11.382

9.  Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.

Authors:  Kathleen E Corey; Matthew J Klebanoff; Angela C Tramontano; Raymond T Chung; Chin Hur
Journal:  Dig Dis Sci       Date:  2016-01-29       Impact factor: 3.199

Review 10.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.

Authors:  Chris Estes; Homie Razavi; Rohit Loomba; Zobair Younossi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-12-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.